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Abstract 
Background: IgA vasculitis (IgAV, Henoch-Schönlein purpura) is a small-vessel vasculitis most 
common in children but also occurring in adults.  Case series have suggested that IgAV may be 
associated with cardiovascular disease and venous thromboembolism, but this has not been 
evaluated in population-based studies.  Renal disease and hypertension are possible complications 
of the disease with unknown incidence. 
Methods: Using a large United Kingdom primary care database, we conducted an open retrospective 
matched cohort study of cardiovascular, venous thrombotic and renal outcomes in adult-onset and 
childhood-onset IgAV.  Control participants were selected at a 2:1 ratio, matched for age and sex.  
Adjusted hazard ratios (aHRs) were calculated using Cox proportional hazards models. 
Results: 2,828 patients with adult-onset IgAV and 10,405 patients with childhood-onset IgAV were 
compared with age- and sex-matched controls.  There was significantly increased risk of 
hypertension (adult-onset aHR 1.42, 95%CI 1.19-1.70, p<0.001; childhood-onset aHR 1.52, 95% CI 
1.22-1.89, p<0.001) and stage G3-G5 chronic kidney disease (adult-onset aHR 1.54, 95%CI 1.23-1.93, 
p<0.001; childhood-onset aHR 1.89, 95%CI 1.16-3.07, p=0.010).  There was no evidence of 
association with ischaemic heart disease, cerebrovascular disease or venous thromboembolism.  All-
cause mortality was increased in the adult-onset IgAV cohort compared to controls (aHR 1.27, 95%CI 
1.07-1.50, p=0.006). 
Conclusions: Patients with IgAV are at increased risk of hypertension and CKD compared to 
individuals without IgAV; analysis restricted to adult-onset IgAV patients showed increased 
mortality.  Appropriate surveillance and risk factor modification could improve long-term outcomes 
in these patients. 
 
 
  
Introduction 
IgA vasculitis (IgAV), also termed Henoch-Schönlein purpura, is a small-vessel vasculitis most 
frequently affecting children[1].  IgAV is the commonest childhood vasculitis in the United Kingdom, 
with estimated annual incidence of 20/100,000 children under the age of 17 years according to the 
largest regional study[2].  However, incidence rates vary widely between study populations, and, 
furthermore, these may represent underestimates of true incidence[3].  The epidemiology of adult-
onset IgAV is less well-studied, but hospital-based studies indicate an estimated annual incidence of 
0.8-1.8/100,000 population[3].   
IgAV may be complicated by glomerulonephritis[4] and it is thought that adult-onset IgAV is 
associated with increased risk and severity of renal involvement compared to childhood disease[5,6].  
However, long-term health outcomes of adult-onset IgAV are not well characterised.  Most evidence 
regarding complications of IgAV in adults derives from case reports and case series[7]; there is need 
for controlled epidemiological studies to address this question.  
Other outcomes associated with IgAV are unknown.  Multiple case reports have raised the possibility 
of associations between IgAV and venous thromboembolism (VTE), hypertension and ischaemic 
heart disease (IHD) in both children and adults[8-19].  However, many cases involved patients with 
additional risk factors, making the role of IgAV unclear.  To date, the incidence of these outcomes 
has not been examined in a large cohort study.  Furthermore, there is emerging evidence that 
patients with other vasculitides have increased incidence of cardiovascular disease[20,21] and 
receive inadequate management of cardiovascular risk[22]. 
This study aims to calculate incidence of IgAV in adults and children, and to quantify risk of 
important complications in adult and childhood-onset disease, in particular, risk of cardiovascular, 
thrombo-embolic and renal outcomes.  These data will facilitate prognostication in such patients, 
thus informing strategies for surveillance and risk factor modification in routine care.   
 
Methods 
Study design 
Incidence and prevalence of IgAV 
To calculate IgAV incidence, annual cohort studies were performed between 1st January 2005 and 
31st December 2016. To estimate prevalence, sequential cross-sectional studies were carried out on 
1st January each calendar year from 2005 to 2016. 
Chronic outcomes 
An open retrospective matched cohort study was performed to compare long-term cardiovascular, 
venous thromboembolic and renal outcomes in adults and children diagnosed with IgAV and 
randomly-selected age- and sex-matched controls without a diagnosis.  The study period was 1st 
January 1995 to 15th May 2017.  
Data source 
Data were extracted from The Health Improvement Network (THIN) database, which comprises 
anonymised medical records for 3.6 million active patients from >675 general practices, as 
previously reported[23,24].  Patient data are derived from practices using Vision electronic medical 
record software, which stores information in a hierarchical system of clinical (Read) codes[25].  THIN 
includes information on patient demographics, diagnoses, prescriptions, and investigations.  THIN 
has previously been validated for studies of cardiovascular and renal outcomes[26,27], and for 
studies of VTE risk[28]. It is broadly representative of the UK population in terms of demographics, 
disease prevalence and mortality rates[23].  To maximise data quality, general practices were only 
included in this study from the latest of one year after they began using Vision software and one 
year after their acceptable mortality recording (AMR) date[24].  Diagnosis was based on Read codes 
which registered a clinical diagnosis of Henoch Schonlein Purpura, and not IgA deposition within 
tissues. 
 
Study population 
Incidence and prevalence of IgAV 
Adults and children with no record of a IgAV diagnosis at the beginning of each one-year study 
period were included in the annual incidence cohorts.  The eligible populations were followed from 
1st January every year until the earliest of the following dates: IgAV diagnosis, patient left the 
practice, death, or 31st December of that year.  Annual prevalence is reported per 100,000 
population.  
Chronic outcomes 
In the adult-onset IgAV cohort, patients were eligible for inclusion if they had a clinical code for IgAV 
recorded at age ≥16 years.  Inclusion in the childhood-onset IgAV cohort was restricted to patients 
with recorded diagnosis of IgAV before the age of 16 years.  For each patient with IgAV, two age and 
sex-matched control patients were randomly selected from a pool of eligible controls. All patients 
were required to be registered with their general practice for at least one year before study entry. 
Index date in the exposed group was the date of first documentation of IgAV after study entry for 
incident cases (newly diagnosed patients), or date of study entry for prevalent cases (patients with 
an existing diagnosis).  To avoid immortal time bias[29], controls were assigned the same index date 
as their corresponding exposed patient.  Participants were followed up until the earliest of the 
following dates: outcome event, death, patient left practice, practice stopped contributing to the 
database, and study end. 
Outcomes 
In patients with adult-onset IgAV, primary outcomes were IHD, VTE, stroke/TIA, hypertension, stage 
G3-G5 CKD and all-cause mortality.  IHD, VTE, stroke/TIA and hypertension were defined by clinical 
(Read) codes; stage G3-G5 CKD was defined by new-onset estimated glomerular filtration rate 
(eGFR) <60mls/min/1.73m2 on two consecutive measurements separated by at least 90 days[30].  
Clinical codes were selected based on QOF business rules and previously published studies[31,32].   
For hypertension, a sensitivity analysis was performed using a lag period of one year to test whether 
this represented a chronic outcome or was solely related to the acute illness.   
In the childhood-onset IgAV cohort, primary outcomes were hypertension, VTE and CKD.  IHD, 
stroke/TIA and mortality were not studied in this cohort due to low incidence in this age group and 
short follow-up period.   
 
Analysis 
Annual incidence rates (IR) of IgAV were calculated by dividing the number of newly diagnosed IgAV 
patients by person-years at risk for adults and children separately.   
Cox proportional hazards models were used to calculate crude hazard ratios (HR) and adjusted 
hazard ratios (aHR) for each outcome in IgAV compared to controls.  Breslow’s method was used to 
handle tied survival times where required.  All models were adjusted for the following covariates: 
age, sex, BMI category, Townsend deprivation quintile, and smoking status.  Additionally, the models 
for IHD and stroke/TIA were adjusted for baseline diabetes, hypertension, and lipid-lowering drug 
prescription; the model for hypertension was adjusted for baseline diabetes and lipid-lowering drug 
prescription; the model for CKD was adjusted for baseline diabetes and hypertension; and the model 
for all-cause mortality was adjusted for lipid-lowering drug prescription and Charlson co-morbidity 
index (CCI).  For childhood-onset IgAV, BMI category, lipid-lowering drug prescription and smoking 
status were not included in the models.  BMI recorded closest to index date was categorised as ‘<25 
kg/m2’, ‘25-30 kg/m2’ (overweight) and ‘>30 kg/m2’ (obesity); smoking status was categorised as 
‘smoker’, ‘ex-smoker’ and ‘non-smoker’.  Social deprivation was categorised according to Townsend 
deprivation quintile[33].  CCI was categorised as ‘0’, ‘1’, ‘2’, or ‘>2’[34].  Separate categories were 
created for missing data, which were included in the regression analyses. 
Baseline renal function was not adjusted for in the primary analysis due to limited availability of 
creatinine measurements before the index date.  A sensitivity analysis was performed in which all 
models were adjusted for baseline eGFR. 
For the adult- and childhood-onset studies, all patients without a record of the outcome under study 
at baseline were included in the primary analysis.  For the CKD study, primary analysis included only 
patients with an eGFR >60mls/min/1.73m2 at baseline.  Sensitivity analyses were performed in 
which: 1) patients with missing baseline eGFR values were included and categorised as having 
normal renal function; and 2) all patients were included regardless of baseline eGFR, assuming that 
baseline eGFR might reflect transient residual renal impairment. 
To ensure that results are applicable to disease of adult onset, a sensitivity analysis was performed 
using incident (newly diagnosed, definite adult-onset) adult IgAV cases only. 
Analyses were performed using STATA 14.0.  Statistical significance was set at p<0.05.   
 
Results 
Incidence of IgAV in adults and children 
Between 2005 and 2016, incidence of childhood-onset IgAV was 27.22 per 100,000 person-years; 
incidence of adult-onset IgAV was 2.20 per 100,000 person-years (Fig. 1; baseline characteristics are 
summarised in Table S2).  Mean (SD) age at diagnosis was 6.68 years (3.41) years for children and 
38.1 (18.8) years for adults.  Whilst IgAV incidence remained stable, prevalence of both adult- and 
childhood-onset IgAV increased over the study period.  Between 2005 and 2016, prevalence of 
adult-onset IgAV increased from 34 to 44 per 100,000 population; prevalence of childhood-onset 
IgAV increased from 621 to 846 per 100,000 population. 
Outcomes in adult-onset IgAV 
Baseline characteristics 
There were 2,828 patients with adult-onset IgAV and 5,655 controls.  Median (IQR) follow-up was 
similar in both cohorts: 4.91 (2.07-9.08) years in the IgAV cohort and 4.99 (2.18-9.05) years in the 
control cohort. 
Mean age at study entry was 43 years in both exposed and unexposed cohorts.  Both cohorts had 
48.4% males. At baseline renal impairment (eGFR <60mls/min/1.73m2) was more common in 
patients with IgAV (6.86% vs. 4.05% in unexposed).  Similar differences between those with and 
without IgAV were observed for hypertension (18.5% vs. 13.0%), diabetes mellitus (5.3% vs. 3.7%), 
VTE (1.8% vs. 1.1%), lipid-lowering drug prescription (11.1% vs. 5.0%) and CCI (15.28% vs. 7.35% with 
≥2 comorbidities).  Patients with IgAV were less likely to be current smokers (18.5% vs. 22.8%).  The 
cohorts were similar with respect to BMI and Townsend deprivation quintile (Table 1). 
Hypertension 
196 IgAV patients (6.93%) received a diagnosis of hypertension, compared to 315 (5.57%) controls 
(Table 2); incidence was 15.26 and 11.18 per 1,000 person-years respectively: aHR 1.42 (95%CI 1.19-
1.70).  Cumulative hazard curves are shown in Fig. 2.  Results were robust in two sensitivity analyses 
restricting outcome to hypertension diagnosed at least one year after the index date and restricting 
to incident IgAV cases and their matched controls (Table S2).   
Ischaemic heart disease and cerebrovascular disease 
53 patients (1.87%) with adult-onset IgAV and 104 (1.84%) controls were diagnosed with IHD, 
corresponding to IRs of 3.32 and 3.20 per 1,000 person-years respectively.  There was no evidence of 
association between IgAV and risk of IHD (aHR 1.08, 95%CI 0.77-1.52).  52 patients with IgAV (1.84%) 
and 109 controls (1.93%) experienced a stroke/TIA, with IRs of 3.14 and 3.26 per 1,000 person-years 
respectively.  There was no evidence of association between IgAV and risk of stroke/TIA (aHR 0.95, 
95%CI 0.68-1.32).   
Venous thromboembolism 
28 patients with adult-onset IgAV (0.99%) and 46 controls (0.81%) were coded with a VTE event; 
incidence was 1.67 and 1.36 per 1,000 person-years respectively.  Crude and adjusted HRs were not 
statistically significant: aHR 1.21 (95%CI 0.76-1.95). 
Chronic kidney disease 
There were 134 incident cases of CKD stages G3-5 (5.11%) in the adult-onset IgAV cohort, compared 
to 185 (3.42%) in controls; incidence was 8.72 and 5.75 per 1,000 person-years respectively: aHR 
1.54 (95%CI 1.23-1.93).  This association remained significant in all sensitivity analyses, including 
adjustment for baseline eGFR (Table S2).   
All-cause mortality  
There were 238 deaths (8.42%) in the adult-onset IgAV cohort and 348 (6.15%) in the control cohort, 
corresponding to mortality rates of 13.93 and 10.12 per 1,000 person-years respectively.  In the 
primary analysis, all-cause mortality was significantly increased in the adult-onset IgAV cohort 
compared to controls: aHR 1.27 (95%CI 1.07-1.50).  However, in a sensitivity analysis using incident 
cases and their controls only, the effect was not statistically significant (aHR 1.09, 95%CI 0.83-1.42).  
Adjusting for baseline eGFR did not affect the results for any outcome (Table S3). 
  
 Outcomes in childhood-onset IgAV 
Baseline characteristics 
10,405 patients with incident or prevalent childhood-onset IgAV were identified and matched to 
20,810 controls without IgAV.  Mean (SD) age at diagnosis for the IgAV cohort was 6.68 (3.4); mean 
age at study entry was 17.6 (13.1) years and 53% were male in both cohorts.  Median (IQR) follow-up 
was similar: 4.86 (2.06-9.08) years in the IgAV cohort and 4.98 (2.17-9.86) years in controls. At 
baseline, more patients with IgAV had hypertension (1.78% vs. 1.13%) and VTE (0.28% vs 0.18%) 
compared to controls (Table 1).  The cohorts were also similar with respect to baseline renal 
function, Townsend deprivation quintile and smoking status.   
Hypertension 
139 patients with IgAV (1.34%) and 193 controls (0.93%) had hypertension (Table 3); incidence was 
2.29 and 1.57 per 1,000 person-years respectively: aHR 1.52 (95%CI 1.22-1.89).  This association 
remained significant in all of the sensitivity analyses performed (Table S3). Cumulative hazard curves 
are shown in Fig. 3. 
Venous thromboembolism 
In the childhood-onset IgAV cohort, 25 patients (0.24%) experienced VTE, compared to 46 controls 
(0.22%); incidence was 0.40 and 0.37 per 1,000 person-years respectively.  There was no evidence of 
association between childhood-onset IgAV and VTE (aHR 1.10, 95%CI 0.68-1.79).  
Chronic kidney disease 
There were 32 incident cases of CKD (0.31%) in patients with IgAV compared to 34 (0.16%) in the 
controls; incidence was 0.51 and 0.27 per 1,000 person-years respectively: aHR 1.89 (95%CI 1.16-
3.07; see Table S3).   
 
Discussion 
In this population-based study, we show that, compared to an age- and sex-matched control 
population, childhood and adult-onset IgAV is associated with increased risk of hypertension and 
CKD.  Adult-onset IgAV was not associated with IHD, cerebrovascular disease or VTE.   
Annual IgAV incidence from 2005 to 2016 in children (27.22 per 100,000 person-years) and adults 
(2.20 per 100,000 person-years) was marginally higher than previously reported (20 and 0.8-1.8 per 
100,000 person-years in children and adults respectively), likely due to the different case-finding 
strategies employed[2,3].  Previous studies likely underestimated IgAV incidence as they had access 
to less comprehensive datasets.  Whilst incidence remained stable over the study period, prevalence 
of adult- and childhood-onset IgAV increased.  This could be explained by improved documentation 
of existing IgAV diagnoses, or may reflect increased patient survival.  The former explanation is more 
likely given the short time period over which this increase occurred. 
To our knowledge, this is the first controlled study examining incidence of IHD, stroke/TIA and VTE in 
adult patients with IgAV.  Despite evidence from case series suggesting that IgAV confers increased 
risk of these outcomes[8–19], we found no evidence of association between IgAV and  IHD, 
stroke/TIA or VTE.  We note that incidence of VTE was low in this cohort (1.67 per 1,000 person-
years).  VTE may be an isolated acute event unrecorded in general practice records, and therefore 
this result should be interpreted with caution. 
Although hypertension has been associated with poor outcomes in some patients with IgAV[35], 
incidence of hypertension in childhood- and adult-onset IgAV was previously unknown.  This study 
revealed similar risk for children and adults.  The effect could be explained by renal manifestations 
of IgAV or by use of medications such as non-steroidal anti-inflammatory drugs and corticosteroids.  
The association remained significant in a sensitivity analysis using only hypertension recorded at 
least one year post-index date, suggesting that it is not solely an acute feature of the disease.  
IgAV is thought to have a poorer renal prognosis in adult patients than in children[5,6,36].  In 
patients with adult-onset IgAV, incidence of stage G3-5 CKD was 8.72 per 1,000 person-years, with a 
54% increase in risk compared to controls.  In patients with childhood-onset IgAV, incidence of CKD 
was much lower (0.51 per 1,000 person-years) but with a similar HR.  The increased incidence of CKD 
in adults compared to children may be explained by a higher burden of co-morbidity and renal 
impairment at baseline. 
A 35% increase in all-cause mortality was observed in adult-onset IgAV patients compared to 
controls.  However, this effect was no longer statistically significant in a sensitivity analysis including 
only incident cases of IgAV.  This may be explained by reduced length of follow-up when only 
incident cases are considered.   
Strengths and limitations 
Definition of exposure status depended on accurate coding of IgAV diagnosis in primary care medical 
records.  These records do not include information on whether IgAV was diagnosed based solely on 
clinical criteria, or whether biopsy findings were used.  We are unable to identify patients with renal 
involvement at diagnosis and recognise that there may be stronger associations with the outcomes if 
the cohort is restricted to patients with biopsy-proven IgAV, as previously shown in patients with 
biopsy-proven Henoch-Schönlein nephritis[37].   
Alternatively, other vasculitides, such as microscopic polyangiitis (MPA), may have been 
misdiagnosed as IgAV in the absence of histological investigation.  Inclusion of such patients could 
increase the incidence of complications such as CKD.  Although widespread testing for anti-
neutrophil cytoplasm autoantibodies has been available since the 1990s, we have no data on ANCA 
testing and cannot exclude that this diagnosis may have been missed in some cases. 
It is possible that patients with greater disease severity were selectively coded in primary care, 
leading to overestimation of effect size.  However, our incidence and prevalence estimates were 
similar, if not slightly higher than previously reported.  Similarly, inaccurate coding of outcomes is a 
potential source of error.  CKD is likely to be under-diagnosed in primary care[38], so practice 
records may underestimate its incidence.  To minimise this risk, CKD was defined by eGFR criteria 
not clinical codes.   
A further caveat is uncertainty regarding classification of IgAV as adult-onset.  In the primary 
analysis, all adult IgAV patients with coded date of diagnosis after their 16th birthday were included.  
However, some cases may have been inappropriately defined as adult-onset, for example if coded 
when the patient moved to a new practice.  Nevertheless, results were replicated in sensitivity 
analyses using incident adult IgAV cases only, showing that our findings are robust to stricter 
definitions of adult-onset IgAV. 
When considering cardiovascular outcomes in patients with adult-onset IgAV, it should be noted that 
the affected population was relatively young (mean age 43.3 years at study entry).  Therefore, it is 
possible that length of follow-up in this study was insufficient to detect increased risk of IHD.   
Finally, this study could be influenced by surveillance bias.  Patients with IgAV may receive closer 
monitoring of blood pressure and renal function in primary care.  This may contribute to the higher 
CCI scores observed in patients with adult-onset IgAV compared to controls.   
Despite these limitations, a strength of this population-based study design is its external validity.  
Patients with IgAV and control participants were included from a primary care database which is 
broadly representative of the UK population in terms of ethnicity, chronic disease prevalence and 
mortality rates[23].   
 
Conclusion 
This retrospective cohort study demonstrates associations between IgAV and hypertension and CKD.  
These findings emphasise the importance of blood pressure and renal function monitoring in 
patients with IgAV.  Our data also suggest that IgAV should not be considered a “single hit” disease, 
but that clinicians should monitor for long-term sequelae.  Further research is required to clarify the 
cause of hypertension in patients with IgAV, and to investigate whether such patients suffer from 
additional long-term sequelae than that are currently unrecognised.   
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Key points 
What is already known about this subject? 
• IgAV is recognised to occur in both children and adults however the incidence and prevalence, 
especially in adults, is unknown in large populations based in primary care 
• IgAV is associated with long-term complications including chronic kidney disease. Small case series 
have previously suggested a predisposition to ischaemic heart disease and venous 
thromboembolism in some patients.  
 
What does this study add? 
• The risk of hypertension and CKD is significantly increased in adult-onset and childhood-onset IgAV 
compared to the general population 
• IgAV is not significantly associated with ischaemic heart disease or venous thromboembolism in 
this study. The young age of most patients and short follow-up in this study mean longer follow-up is 
required to address the risk of ischaemic heart disease. 
 
How might this impact on clinical practice? 
• Clinicians looking after patients who have had IgAV should routinely monitor for hypertension and 
CKD 
 
 
Tables 
Baseline summary characteristics table 
Table 1: Baseline characteristics of the adult- and childhood-onset IgAV cohorts with corresponding 
controls.  Adult-onset patients include all incident and prevalent IgAV cases with a date of diagnosis 
after the age of 16 years.  Childhood-onset patients include all incident and prevalent IgAV cases 
with a date of diagnosis before the age of 16 years.  Controls were age- and sex-matched in a 2:1 
ratio. 
Baseline Characteristics (Standard Deviation or Percentage) 
  
Adult-onset IgAV Childhood-onset IgAV 
Exposed Unexposed Exposed  Unexposed 
Number of patients 2,828 5,655 10,405 20,810 
Median follow-up 
period (years) 
4.91 (IQR 2.07-
9.08) 
4.99 (IQR 2.18-
9.05) 
4.86 (IQR 2.06-
9.08) 
4.98 (IQR 2.17-
9.86) 
Mean age at study 
entry (years)† 
43.33 (18.8) 43.33 (18.7) 17.57 (13.12) 17.59 (13.13) 
Mean age at IgAV 
diagnosis 
38.09 (18.8) N/A 6.68 (3.41) N/A 
Gender (Male) 1,370 (48.4%) 2,739 (48.4%) 5,545 (53.29%) 11,090 (53.29%) 
Gender (Female) 1,458 (51.6%) 2,916 (51.6%) 4,860 (46.71%) 9,720 (46.71%) 
Mean body mass 
index (BMI) 
26.9 (6.1) 26.2 (5.5) N/A N/A 
Smoking status  
Current smoker 522 (18.5%) 1,289 (22.8%) 1,178 (11.32%) 2,102 (10.10%) 
Ex-smoker 525 (18.6%) 845 (14.9%) 528 (5.07%) 904 (4.34%) 
Non-smoker 1,525 (53.9%) 2,825 (50.0%) 2,751 (26.44%) 5,427 (26.08%) 
Not available 256 (9.05%) 696 (12.31%) 5,948 (57.16%) 12,377 (59.48%) 
Hypertension 523 (18.5%) 734 (13.0%) 185 (1.78%) 236 (1.13%) 
Diabetes mellitus 149 (5.3%) 210 (3.7%) 66 (0.63%) 133 (0.64%) 
VTE 52 (1.8%) 61 (1.1%) 29 (0.28%) 37 (0.18%) 
IHD 139 (4.9%) 220 (3.9%) N/A N/A 
Stroke and TIA 68 (2.4%) 107 (1.9%) N/A N/A 
eGFR category  
>90 ml/min per 1.73 
m2 
639 (22.60%) 856 (15.14%) 116 (0.56%) 100 (0.96%) 
60-90 ml/min per 1.73 
m2 
697 (24.65%) 1,160 (20.51%) 121 (0.58%) 157 (1.51%) 
30-59 ml/min per 1.73 
m2 
164 (5.80%) 209 (3.70%) 1,339 (6.43%) 707 (6.79%) 
<30 ml/min per 1.73 
m2 
30 (1.06 20 (0.35%) 1,358 (6.53%) 642 (6.17%) 
Not available 1,298 (45.90%) 3,410 (60.30%) 17,876 (85.90%) 8,799 (84.57%) 
Lipid regulating 
medication use 
313 (11.1%) 506 (5.0%) N/A N/A 
Current contraceptive 
use* 
336 (23.1%) 572 (19.6%) 799 (16.44%) 1,432 (14.73%) 
Townsend 
deprivation quintile  
 
(Least deprived) 1    622 (22.0%) 1,231 (21.8%) 2,216 (21.30%) 4,529 (21.76%) 
2 542 (19.2%) 1,161 (20.5%) 1,927 (18.52%) 3,863 (18.56%) 
3 557 (19.7%) 1,080 (19.1%) 1,968 (18.91%) 4,055 (19.49%) 
4 476 (16.8%) 955 (16.9%) 1,856 (17.84%) 3,633 (17.46%) 
5 334 (11.8%) 670 (11.9%) 1,293 (12.43%) 2,614 (12.56%) 
Not available 297 (10.5%) 558 (9.9%) 1,145 (11.0%) 2,116 (10.17%) 
Charlson co-
morbidity index 
 
0 1,806 (63.86%) 4,176 (73.85%) N/A N/A 
1 590 (20.86%) 1,063 (18.80%) N/A N/A 
2 259 (9.16%) 258 (4.56%) N/A N/A 
> 2 173 (6.12%) 158 (2.79%) N/A N/A 
†Note that many patients had a IgAV diagnosis prior to study entry – prevalent cases 
*Current contraceptive use percentage reported for females only.  
Summary of adult-onset IgAV outcomes 
Table 2: Summary of primary outcomes in adult-onset IgAV cases and corresponding controls.   
  
Hypertension 
Ischaemic heart 
disease 
Stroke/TIA Venous thrombo-
embolism 
Chronic kidney 
disease 
All-cause mortality 
IgAV Control IgAV Control IgAV Control IgAV Control IgAV Control IgAV Control 
Number of 
Patients 
2,305 4,921 2,689  5,435 2,760 5,548 2,776 5,594 2,487 5,225 2,828 5,655 
Numbers of 
Outcomes 
196 315 53 104 68 107 28 46 134 185 238 348 
Person-years 12,847.60 28,174.46 15,974 32,542.38 16,552.39 33,468.58 16,771.07 33,813.95 15,359.92 32,167.31 17,085.13 34,391.52 
Incidence 
Rate (per 
1,000 
person-
years) 
15.26 11.18 3.32 3.20 3.14 3.26 1.67  1.36 8.72 5.75 13.93 10.12 
Crude 
Hazard Ratio 
(95% CI) 
1.36 (1.14-1.63) 1.04 (0.75-1.44) 0.96 (0.69-1.34) 1.22 (0.76-1.96) 1.52 (1.22-1.90) 1.37 (1.17-1.62) 
p-value 0.001 0.829 0.814 0.401 <0.001 <0.001 
Adjusted 
Hazard Ratio 
(95% CI)  
1.42 (1.19-1.70) 1.08 (0.77-1.52) 0.95 (0.68-1.32) 1.21 (0.76-1.95) 1.54 (1.23-1.93) 1.27 (1.07-1.50) 
p-value <0.001 0.637 0.758 0.424 <0.001 0.006 
 Summary of childhood-onset IgAV outcomes 
Table 3: Summary of primary outcomes in childhood-onset IgAV cases and corresponding controls.   
  
Hypertension 
Venous thrombo-
embolism 
Chronic kidney 
disease 
IgAV Control IgAV Control IgAV Control 
Number of 
Patients 
10,220 20,574 10,376 20,773 10,370 20,763 
Numbers of 
Outcomes 
139 193 25 46 32 34 
Person-years 60,753.91 123,318.1 62,333.31 125,359.3 62,185.31 125,362.3 
Incidence 
Rate (per 
1,000 
person-
years) 
2.29 1.57 0.40 0.37 0.51 0.27 
Crude 
Hazard Ratio 
(95% CI) 
1.46 (1.17-1.81) 1.08 (0.66-1.75) 1.90 (1.17-3.08) 
p-value 0.001 0.762 0.009 
Adjusted 
Hazard Ratio 
(95% CI)  
1.52 (1.22-1.89) 1.10 (0.68-1.79) 1.89 (1.16-3.07) 
p-value <0.001 0.697 0.010 
 
  
Figures 
 
Figure 1: Annual incidence and prevalence for childhood-onset and adult-onset IgAV from 2005 to 
2016. 
1A) Annual incidence (squares) and prevalence (circles) for childhood-onset IgAV (95% confidence 
intervals shown).  1B) Annual incidence (squares) and prevalence (circles) for adult-onset IgAV (95% 
confidence intervals shown). 
 Figure 2: Cumulative hazard curves for outcomes in adult-onset IgAV 
Cumulative hazard curves are displayed for each of the six outcomes under study in the adult-onset 
IgAV cohort.  
 Figure 3: Cumulative hazard curves for outcomes in childhood-onset IgAV 
Cumulative hazard curves are displayed for each of the three outcomes under study in the 
childhood-onset IgAV cohort. 
  
 
 
Figure S1 (supplementary): Visual representation of the study timeline and selection process 
The exposed cohort were identified by IgAV Read codes, and their controls were matched in a 2:1 
ratio for age and sex.  The index date for IgAV patients was either the date of diagnosis (for incident 
cases) or the date on which the patient became eligible to participate (for prevalent cases).  Controls 
were selected at the same index date as their corresponding IgAV patient to mitigate immortal time 
bias.   
To maximise data quality, patients were eligible for participation one year after the latest of the 
following dates: i) registration at the general practice, ii) introduction of Vision EMR software at the 
practice, iii) practice acceptable mortality recording (AMR) date, which is an indication of accurate 
and timely recording of information by the practice.  The one-year latent period is applied to give 
sufficient time for the practice to record all important covariates.  The patient exit date is the earliest 
of the following dates: i) development of outcome under study, ii) date of death, iii) date of transfer 
from general practice, iv) date of last data collection from general practice. 
 
 
